E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium
Hisani N. Horne(United States Food and Drug Administration), Laura J. van’t Veer(University of California, San Francisco), Stephen M. Hewitt(National Institutes of Health), Maya Palakal(John Wiley & Sons (United States)), Fergus J. Couch(Mayo Clinic), Jenny Chang‐Claude(Universität Hamburg), Michael E. Jones(Institute of Cancer Research), Kathryn J. Ruddy(Mayo Clinic in Arizona), Anthony J. Swerdlow(Institute of Cancer Research), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Päivi Heikkilä(University of Helsinki), Carolien H. M. van Deurzen(Erasmus MC), Roger L. Milne(The University of Melbourne), Christi J. van Asperen(Loyola University Medical Center), Peter Devilee(Leiden University), A. Mieke Timmermans(Erasmus MC Cancer Institute), Douglas F. Easton(University of Cambridge), Javier Benı́tez(Spanish National Cancer Research Centre), Katarina Ćuk(German Cancer Research Center), Heli Nevanlinna(University of Helsinki), Carl Blomqvist(University of Helsinki), Melissa A. Troester(University of North Carolina at Chapel Hill), José Ignacio Arias Pérez, Flora F. Van Leeuwen(The Netherlands Cancer Institute), David Hardisson(Universidad Autónoma de Madrid), Reijo Sironen(University of Eastern Finland), John W.M. Martens(Erasmus MC), Maartje J. Hooning(Erasmus MC Cancer Institute), Hannah Oh(University of Illinois Urbana-Champaign), Nick Orr(United States Department of Health and Human Services), Maria Tengström(Kuopio University Hospital), Renske Keeman(The Netherlands Cancer Institute), Hermann Brenner(Universidad de Granada), Jaana M. Hartikainen(University of Eastern Finland), Renata Cora(National Cancer Institute), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Janet E. Olson(Cornell University), Vincent T.H.B.M. Smit(Leiden University Medical Center), Taru Muranen(Karolinska Institutet), Abigail Thomas(Mayo Clinic in Florida), Mark E. Sherman(National Cancer Institute), Caroline Seynaeve(Erasmus MC), Bernd Holleczek(Krebsregister Saarland), Ursula Eilber(University of Helsinki), Manjeet K. Bolla(University of Cambridge), Minouk J. Schoemaker(Institute of Cancer Research), Kai-Uwe Saum(German Cancer Research Center), Marjanka K. Schmidt(University of Cambridge)
Cited by 60
Related Papers
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
|JAMA Oncology|2016|6.3k
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.4k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k